Beam Therapeutics (BEAM) Up 5.7% Since Last Earnings Report: Can It Continue?

Beam Therapeutics (BEAM) shares have increased by 5.7% since its last earnings report, underperforming the S&P 500, with earnings estimates remaining flat over the past month. The stock holds a Zacks Rank #3 (Hold), suggesting an expected in-line return in the near term, and receives poor Growth and Value scores of F, though it has a Momentum Score of C. Comparatively, Bristol Myers Squibb (BMY), another stock in the same industry, has gained 0.7% over the past month, reporting a 5.6% year-over-year decrease in revenues and expecting a 19.3% year-over-year decrease in earnings per share for the current quarter.

Analysis

Beam Therapeutics Inc. (BEAM) has experienced a 5.7% increase in its share price over the past month since its last earnings report, a performance that lagged the S&P 500. During this period, analyst earnings estimates for BEAM have remained unchanged. The company currently holds a Zacks Rank #3 (Hold), indicating an expectation of in-line market performance in the coming months. Its fundamental assessment through Zacks VGM Scores reveals a poor Growth Score of F and a low Value Score of F, placing it in the lowest quintile for value investors, although its Momentum Score is a more moderate C. The aggregate VGM Score for BEAM is F. In comparison, Bristol Myers Squibb (BMY), a peer in the Zacks Medical - Biomedical and Genetics industry, saw a 0.7% share price gain over the same period. Bristol Myers reported a 5.6% year-over-year decrease in revenues to $11.2 billion for the quarter ended March 2025, though its EPS improved to $1.80 from -$4.40 a year ago. For the current quarter, Bristol Myers is projected to report earnings of $1.67 per share, a 19.3% year-over-year decline, and its Zacks Consensus Estimate has seen a marginal +0.1% upward revision in the last 30 days, contributing to its Zacks Rank #3 (Hold) and a strong VGM Score of A.

Key Decisions for Investors

• Given Beam Therapeutics' (BEAM) Zacks Rank #3 (Hold), flat earnings estimates, and weak Growth and Value scores despite recent share price appreciation, investors might consider maintaining existing positions rather than initiating new ones pending further catalysts or estimate revisions.
• The underperformance of BEAM relative to the S&P 500 and its overall VGM Score of F suggest caution, and investors should monitor upcoming earnings for any change in fundamental outlook.
• For Bristol Myers Squibb (BMY), despite a strong VGM Score of A, the anticipated earnings decline and recent revenue contraction warrant a cautious stance, aligning with its Zacks Rank #3 (Hold); investors should watch for sustained improvements in revenue and earnings trends before considering aggressive positions.